Immune checkpoint inhibitors (ICIs) have changed how we think about tumor management.
Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the …

Immunotherapy has revolutionized cancer treatment over the past decade. As it is
increasingly introduced into routine clinical practice, immune-related complications have …

Background Neurological immune-related adverse events (nirAEs) are rare toxicities of
immune-checkpoint inhibitors (ICI). With the increase of ICI oncological indications, their …

Neurological immune-related adverse events (irAEs) due to immune checkpoint inhibitors
(ICI) are rare complications of immunotherapy, particularly dreadful for patients and clinical …

The use of immune checkpoint inhibitors (ICIs) for the treatment of various advanced and
aggressive types of malignancy has significantly increased both survival and long-term …

Objective Describe the demographic data and clinical phenotype of cranial palsy induced by
immune checkpoint inhibitors (CNP-ICI). Methods A systematic literature review of the …

Purpose: Communication atypicalities are considered promising markers of a broad range of
clinical conditions. However, little is known about the mechanisms and confounders …

Cancer therapy relies on new antitumoral drugs called immune checkpoint inhibitors (ICI),
which produce long-lasting anti-tumor responses and lengthen survival, but cause …

La terapia contra el cáncer cuenta con los nuevos inhibidores de puntos de fijación (ICI),
que producen respuestas antitumorales duraderas y alargan la supervivencia pero …

The advancement of immunotherapy has changed cancer treatment. Immune checkpoint
inhibitors (ICIs) are one of the groundbreaking immunotherapies that have offered patients …